What's new

Orphan designation: epertinib Treatment of amyotrophic lateral sclerosis, 26/02/2025 Positive

Orphan designation: epertinib Treatment of amyotrophic lateral sclerosis, 26/02/2025 Positive

Mar 11, 2025 - 11:43
 0
Orphan designation: epertinib Treatment of amyotrophic lateral sclerosis, 26/02/2025 Positive
Orphan designation: epertinib Treatment of amyotrophic lateral sclerosis, 26/02/2025 Positive
Read More

Tags:

Previous Article

LEON marks milestone in becoming UK’s leading omni-channel fast food brand

Next Article

Orphan designation: Autologous CD34+ cell enriched population containing haemato...

Related Posts

Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Date of authorisation: 26/09/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 4, 2025  0

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 10, 2025  0

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Orphan designation: human anti-promyostatin monoclonal ...

Feb 24, 2025  0